Dunhill Financial’s Harmony Biosciences HRMY Stock Holding History

Dunhill Financial’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$27	–	1976
2025 Q4	$27	Buy	+1	New	+$33	﹤0.01%	1846

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Dunhill Financial's HRMY Position: Q1 2026 in Review

Dunhill Financial sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 1 share — an estimated $27 sold.

Dunhill Financial first reported a position in HRMY in Q4 2025 and held it in 1 quarter. The position peaked at $27 in Q4 2025. 311 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

Dunhill Financial reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
Dunhill Financial sold 1 Harmony Biosciences share in Q1 2026, an estimated $27.
Dunhill Financial first reported a position in Harmony Biosciences in Q4 2025 and held it in 1 quarter.
Dunhill Financial's Harmony Biosciences position peaked at $27 in Q4 2025.
311 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Dunhill Financial's 13F filing for Q1 2026, filed 6 May 2026.